Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma

(2016) J. Duerinck et al.   JOURNAL OF NEURO-ONCOLOGY

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

(2015) Aurelie Guislain et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Regulatory T cells are not a strong predictor of survival for patients with glioblastoma

(2015) A. A. Thomas et al.   NEURO-ONCOLOGY

Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model

(2015) Stephanie Du Four et al.   OncoImmunology

Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects

(2014) T. T. Batchelor et al.   CLINICAL CANCER RESEARCH

Immunotherapy for Brain Cancer: Recent Progress and Future Promise

(2014) C. M. Jackson et al.   CLINICAL CANCER RESEARCH

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

(2013) J. Fourcade et al.   CANCER RESEARCH

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity

(2013) Mei-Ling Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors

(2013) Franziska Stehle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

(2013) Alicia S Chung et al.   NATURE MEDICINE

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)

(2013) Markus Hutterer et al.   NEURO-ONCOLOGY

The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression

(2013) Bo Wei et al.   TUMOR BIOLOGY

VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression

(2012) J. C. Doloff et al.   CANCER RESEARCH

Regulatory T Cells Move in When Gliomas Say "I DO"

(2012) B. D. Choi et al.   CLINICAL CANCER RESEARCH

Sorting Through Subsets

(2012) Christopher A. Klebanoff et al.   JOURNAL OF IMMUNOTHERAPY

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

(2012) E. Q. Lee et al.   NEURO-ONCOLOGY

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

(2011) J. Fourcade et al.   CANCER RESEARCH

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY